US Bancorp DE Has $123,000 Stake in iTeos Therapeutics, Inc. (NASDAQ:ITOS)

US Bancorp DE raised its position in shares of iTeos Therapeutics, Inc. (NASDAQ:ITOS) by 206.0% during the 3rd quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm owned 12,076 shares of the company’s stock after purchasing an additional 8,129 shares during the quarter. US Bancorp DE’s holdings in iTeos Therapeutics were worth $123,000 at the end of the most recent quarter.

Other hedge funds also recently modified their holdings of the company. nVerses Capital LLC raised its position in iTeos Therapeutics by 212.5% during the third quarter. nVerses Capital LLC now owns 2,500 shares of the company’s stock valued at $26,000 after buying an additional 1,700 shares during the period. China Universal Asset Management Co. Ltd. increased its holdings in shares of iTeos Therapeutics by 60.4% in the 3rd quarter. China Universal Asset Management Co. Ltd. now owns 7,024 shares of the company’s stock valued at $72,000 after purchasing an additional 2,646 shares during the period. SG Americas Securities LLC purchased a new stake in shares of iTeos Therapeutics in the third quarter worth approximately $126,000. The Manufacturers Life Insurance Company boosted its holdings in shares of iTeos Therapeutics by 6.6% during the second quarter. The Manufacturers Life Insurance Company now owns 11,071 shares of the company’s stock worth $164,000 after purchasing an additional 690 shares during the period. Finally, Zurcher Kantonalbank Zurich Cantonalbank increased its stake in iTeos Therapeutics by 35.9% in the 2nd quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 11,998 shares of the company’s stock valued at $178,000 after buying an additional 3,172 shares during the period. Hedge funds and other institutional investors own 97.16% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of brokerages have issued reports on ITOS. HC Wainwright reissued a “buy” rating and set a $46.00 target price on shares of iTeos Therapeutics in a research note on Friday. JPMorgan Chase & Co. dropped their target price on iTeos Therapeutics from $27.00 to $24.00 and set an “overweight” rating on the stock in a research report on Monday, August 12th. Wells Fargo & Company assumed coverage on iTeos Therapeutics in a report on Tuesday, August 13th. They set an “overweight” rating and a $31.00 price target for the company. Finally, Wedbush restated an “outperform” rating and issued a $25.00 price objective on shares of iTeos Therapeutics in a report on Tuesday.

iTeos Therapeutics Price Performance

NASDAQ ITOS opened at $8.23 on Friday. iTeos Therapeutics, Inc. has a fifty-two week low of $7.99 and a fifty-two week high of $18.75. The stock’s 50-day moving average is $10.40 and its two-hundred day moving average is $13.99. The firm has a market cap of $300.64 million, a P/E ratio of -2.69 and a beta of 1.39.

iTeos Therapeutics Profile

Iteos Therapeutics, Inc, a clinical-stage biopharmaceutical company, engages in the discovery and development of immuno-oncology therapeutics for patients with cancer. The company's lead antibody product candidate, belrestotug, an antagonist of TIGIT or T-cell immunoreceptor with Ig and ITIM domains, which is in Phase 1b clinical trial, as well as used to engage the Fc gamma receptor, or Fc?R to activate dendritic cells, natural killer cells, and macrophages and to promote antibody-dependent cellular cytotoxicity, or ADCC activity.